Results 251 to 260 of about 11,612,374 (304)
Some of the next articles are maybe not open access.
Non‐Viral Vector as Vaccine Carrier
2005Over the last several years, advances in gene-based delivery technology arising from the field of gene therapy have helped revitalize the field of vaccine development. Genetic vaccination encoding antigen from bacteria, virus, and cancer has shown promise in protective humoral and cellular immunity; however, the potential disadvantages of naked DNA ...
Weihsu Claire, Chen, Leaf, Huang
openaire +2 more sources
In Vivo Application of Non-viral Vectors to the Liver
Journal of Drug Targeting, 2002The liver plays a central role in many inherited and acquired genetic disorders, and thus is a potential target for nucleic acid therapies. Despite the great strides made in basic molecular biology over the last two decades successful gene therapy remains elusive.
Paul, Richardso +2 more
openaire +2 more sources
Non-viral Charge Reversal Vectors for pDNA Delivery
2006 International Conference of the IEEE Engineering in Medicine and Biology Society, 2006A synthetic vector that transform from a cationic to an anionic lipid intracellularly is described. This charge-reversal lipid was synthesized and characterized, including the supramolecular complex it forms with DNA. Enhanced gene transfection was observed using this synthetic vector compared to current cationic lipids.
Carla A. H. Prata +4 more
openaire +2 more sources
Non-viral Vectors for Gene Therapy
2020Presently, more than 3400 genes have been associated with diseases [1], some of these pathologies are debilitating, mortal, and without any effective therapeutic options, and this number is expected to increase in the next decade as genomic studies advance.
Clévio Nóbrega +2 more
openaire +1 more source
Endocytosis in gene therapy with non-viral vectors
Wiener Medizinische Wochenschrift, 2016Gene therapy or the delivery of genetic material can be carried out not only with viral vectors, but with non-viral vectors too. Although the use of non-viral carriers is safer, this approach has generally been poorer in terms of transfection efficiency.
openaire +2 more sources
Non-Viral Vectors for Gene Delivery
Nanoscience &Nanotechnology-Asia, 2018Introduction:Gene therapy has emerged out as a promising therapeutic pave for the treatment of genetic and acquired diseases. Gene transfection into target cells using naked DNA is a simple and safe approach which has been further improved by combining vectors or gene carriers.
Aparna Bansal, null Himanshu
openaire +1 more source
pH-responsive shielding of non-viral gene vectors
Expert Opinion on Drug Delivery, 2006PEG shielding of non-viral vectors reduces undesired interactions with the extracellular environment. Combination with cell-binding domains enables in vivo targeting via specific attachment to the target cells. Pegylation, however, also interferes with effective intracellular nucleic acid delivery. Consistently triggered removal of the PEG shield after
Martin, Meyer, Ernst, Wagner
openaire +2 more sources
Development of non-viral vectors for systemic gene delivery
Journal of Controlled Release, 2002One of the major challenges for gene therapy is systemic delivery of a nucleic acid directly into an affected tissue. This requires developing a vehicle which is able to protect the nucleic acid from degradation, while delivering the gene of interest to the specific tissue and specific subcellular compartment.
Feng, Liu, Leaf, Huang
openaire +2 more sources
Gene therapy for haemophilia…yes, but…with non‐viral vectors?
Haemophilia, 2009Summary. High‐purity plasma‐derived and recombinant factors are currently safe and efficient treatment for haemophilia. The mid‐term future of haemophilia treatment will involve the use of modified recombinant factors to achieve advantages such as decreased immunogenicity in inhibitor formation and enhanced efficacy as a result of their longer half ...
A, Liras, S, Olmedillas
openaire +2 more sources
Modular design of non-viral vectors with bioactive components
Trends in Biotechnology, 2004Inefficient gene delivery continues to limit gene therapy applications to both basic and applied sciences. Approaches for engineering vectors increasingly include bioactive components that bind cellular receptors, disrupt membranes, or enhance nuclear transport.
Lonnie D, Shea, Tiffany L, Houchin
openaire +2 more sources